{"product_id":"arct-marketing-mix","title":"(ARCT) Arcturus Therapeutics Holdings Inc. Marketing Mix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDownload Your Competitive Advantage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Arcturus Therapeutics Holdings Inc. 4P's Marketing Mix Analysis summarizes the company’s product offerings, pricing approach, distribution channels, and promotional tactics to clarify market positioning and strategy; the page contains a real preview\/sample of the report so you can evaluate format and depth—purchase the full version to download the complete ready-to-use analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRNA-based medicines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eArcturus Therapeutics Holdings Inc. centers its product mix on RNA-based medicines, using RNA as the core platform for both vaccines and therapeutics. This keeps Company Name in advanced biotechnology, not consumer healthcare, because the value comes from drug discovery, delivery, and clinical development. The platform has already reached commercial validation with its approved COVID-19 vaccine in Japan, while other candidates stay in development.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLUNAR-OTC\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLUNAR-OTC is Arcturus Therapeutics Holdings Inc.'s lead RNA therapy for ornithine transcarbamylase deficiency, a rare urea-cycle liver disorder seen in about 1 in 70,000 births. It targets a high-unmet-need niche with no curative option and severe hyperammonemia risk. In a rare-disease market with small patient counts but high pricing power, this program is a core product pillar.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLUNAR-CF\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLUNAR-CF is Arcturus Therapeutics Holdings Inc.'s precision RNA program for cystic fibrosis lung disease tied to CFTR mutations. Cystic fibrosis affects about 105,000 people worldwide and about 40,000 in the U.S., so the target pool is small but clear. The program shows Arcturus Therapeutics Holdings Inc.'s focus on respiratory genetic disease and mutation-specific therapy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003e2 vaccine programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eArcturus Therapeutics Holdings Inc. has 2 vaccine programs, LUNAR-COV19 and LUNAR-FLU, aimed at infectious disease prevention. This widens the mix beyond rare disease work and gives the Company a second growth lane in respiratory vaccines. The COVID-19 and flu markets are large, recurring demand pools, so these programs can support long-term platform value.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2 vaccine programs: LUNAR-COV19 and LUNAR-FLU\u003c\/li\u003e\n\u003cli\u003eTargets infectious disease prevention\u003c\/li\u003e\n\u003cli\u003eBroadens the mix beyond rare disease therapeutics\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRare disease and infectious disease pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eArcturus Therapeutics Holdings Inc.'s pipeline spans rare liver, respiratory, and infectious diseases, so it can serve more specialty-medicine buyers instead of leaning on one field. That spread lowers single-asset risk and keeps several shots on goal alive as programs move through clinical development. In 2025, this broader mix mattered because pipeline diversification is still a key hedge for small-cap biotech.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRare liver disease broadens specialty access.\u003c\/li\u003e\n\u003cli\u003eRespiratory and infectious disease add scale.\u003c\/li\u003e\n\u003cli\u003eMore programs reduce therapeutic-area dependence.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eArcturus Bets on Rare Disease and Vaccine Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eArcturus Therapeutics Holdings Inc. builds its product mix around RNA medicines, with one approved COVID-19 vaccine in Japan and three main development areas: rare liver disease, cystic fibrosis, and respiratory vaccines. LUNAR-OTC and LUNAR-CF target small, high-need patient groups, while LUNAR-COV19 and LUNAR-FLU add larger prevention markets. This gives the Company both niche pricing power and broader vaccine upside.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProgram\u003c\/th\u003e\n\u003cth\u003eFocus\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLUNAR-OTC\u003c\/td\u003e\n\u003ctd\u003eRare liver disease\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLUNAR-CF\u003c\/td\u003e\n\u003ctd\u003eCystic fibrosis\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLUNAR-COV19\u003c\/td\u003e\n\u003ctd\u003eCOVID-19 vaccine\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLUNAR-FLU\u003c\/td\u003e\n\u003ctd\u003eFlu vaccine\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eDelivers a concise, company-specific 4P’s analysis of Arcturus Therapeutics Holdings Inc.’s product, pricing, placement, and promotion strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eSummarizes Arcturus Therapeutics’ 4Ps in a clear, at-a-glance format that helps teams quickly spot key strategy gaps and opportunities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise, traceable bibliography of industry reports, clinical data, and regulatory filings to speed due diligence and verify Arcturus Therapeutics' market and financial assumptions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePlace\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSan Diego, California HQ\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eArcturus Therapeutics Holdings Inc. is headquartered in San Diego, California, keeping corporate and scientific leadership in the U.S. The city gives it direct access to one of the country’s strongest biotech talent pools and a deep Southern California life-science cluster. That U.S. base also helps it stay close to Nasdaq-linked capital markets and investor coverage.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnited States operating base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eArcturus Therapeutics Holdings Inc. keeps its U.S. operating base in San Diego, California, a top biotech hub with dense FDA, university, and clinical-trial access. This setup supports faster regulator contact, stronger research ties, and easier partnership sourcing across the United States. It also fits a market where California hosts thousands of life-science firms and a deep talent pool.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVinbiocare manufacturing link\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eArcturus Therapeutics Holdings Inc. uses Vinbiocare Biotechnology Joint Stock Company as a manufacturing link for its COVID-19 vaccine work, extending execution beyond its San Diego base. The tie-up helps connect R\u0026amp;D to scaled production, which mattered for ARCT-154, the LUNAR-COVID-19 vaccine candidate. In 2025, Arcturus still had no marketed product revenue, so partnerships like this remain key to turning pipeline assets into supply.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSingapore collaboration network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eArcturus Therapeutics Holdings Inc. uses Singapore as a place base for global R\u0026amp;D, linking with the Singapore Economic Development Board and Duke-NUS Medical School on LUNAR-COV19. That 3-party setup plugs Arcturus into Singapore’s life sciences hub, where the government targets 1.5% of GDP for public R\u0026amp;D support and keeps biotech talent close to clinics and labs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e3-party Singapore R\u0026amp;D network\u003c\/li\u003e\n\u003cli\u003eLUNAR-COV19 collaboration\u003c\/li\u003e\n\u003cli\u003eLinks to life sciences ecosystem\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGlobal partner distribution model\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eArcturus Therapeutics Holdings Inc. uses a partner-led distribution model, so its programs move through collaborators, research institutions, and clinical sites rather than direct retail channels. That fits an early-stage biotech model, where access is built through licensing, trials, and regulatory pathways, not store shelves. In practice, this keeps commercial reach narrow today, but scales through partner networks as assets advance.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePartner-led access, not retail\u003c\/li\u003e\n\u003cli\u003eFlows through clinical channels\u003c\/li\u003e\n\u003cli\u003eFits early-stage biotech\u003c\/li\u003e\n\u003cli\u003eScales via collaborators\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eArcturus’ Global Biotech Footprint Anchors Its Partner-Led Strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eArcturus Therapeutics Holdings Inc. keeps Place focused on biotech hubs, with its San Diego base anchoring R\u0026amp;D, regulator access, and investor links. It also uses Singapore for LUNAR-COV19 collaboration and Vinbiocare Biotechnology Joint Stock Company for manufacturing support, so its reach extends beyond the U.S. In 2025, it still reported no marketed product revenue, which makes partner-led channels central.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePlace\u003c\/th\u003e\n\u003cth\u003eKey fact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSan Diego\u003c\/td\u003e\n\u003ctd\u003eHQ and R\u0026amp;D base\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSingapore\u003c\/td\u003e\n\u003ctd\u003eLUNAR-COV19 collaboration\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVinbiocare\u003c\/td\u003e\n\u003ctd\u003eManufacturing link\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025\u003c\/td\u003e\n\u003ctd\u003eNo marketed product revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eArcturus Therapeutics Holdings Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual document you’ll receive instantly after purchase—no surprises. This Arcturus Therapeutics Holdings Inc. 4P's Marketing Mix analysis is complete, editable, and ready to use, covering Product, Price, Place, and Promotion with concise insights and actionable recommendations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePromotion\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePartner announcements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eArcturus uses partner announcements as a core promotion tool, and the company has named 7 collaborators: Vinbiocare, Janssen, Ultragenyx, CureVac, the Singapore Economic Development Board, Duke-NUS, and Millennium Pharmaceuticals. These deals signal outside validation of Arcturus Therapeutics Holdings Inc.'s mRNA platform and help build trust with investors and drug-development partners. Each announcement also extends reach without heavy consumer ad spend.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical pipeline updates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eArcturus Therapeutics Holdings Inc. promotes clinical progress by spotlighting four named programs: LUNAR-OTC, LUNAR-CF, LUNAR-COV19, and LUNAR-FLU. Pipeline updates help show development momentum and keep investors, partners, and researchers aware of where each program stands. This also reinforces the company’s RNA medicine platform and the scale of its active pipeline.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScientific and medical visibility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eArcturus Therapeutics Holdings Inc. promotes through scientific visibility, with clinical updates on RNA medicines like ARCT-154 and ARCT-032 giving doctors and regulators clear proof points. In 2025, the Company kept its pipeline in public view through research and trial milestones, which is key in biotech where credibility often follows data. That steady disclosure helps support trust before sales do.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eInvestor relations communication\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eArcturus Therapeutics Holdings Inc. uses investor relations as a core promotion tool, because its pipeline is still the main value driver and products are not yet broadly commercial. Through earnings calls, SEC filings, and conference presentations, Company Name explains trial progress, cash use, and strategy so investors can price pipeline risk more clearly.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eShapes market view of pipeline data\u003c\/li\u003e\n\u003cli\u003eSupports trust before broad sales\u003c\/li\u003e\n\u003cli\u003eUses disclosure to frame milestones\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRegulatory and publication channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eArcturus Therapeutics Holdings Inc. leans on regulatory filings and scientific publications because biotech trust is built on data, not ads. That matters more when investors focus on safety and efficacy readouts from clinical updates, conference posters, and peer-reviewed papers. In FY2025, this kind of channel is more relevant than mass-market promotion for a company still driven by pipeline milestones.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRegulatory updates build credibility\u003c\/li\u003e\n\u003cli\u003ePublications support efficacy claims\u003c\/li\u003e\n\u003cli\u003eClinical data drives the message\u003c\/li\u003e\n\u003cli\u003eTrust matters more than ad spend\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eArcturus FY2025: Data-Driven Biotech Promotion Centers on Milestones\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIn FY2025, Arcturus Therapeutics Holdings Inc. promoted mainly through data, not ads: 7 named collaborators, 4 highlighted programs, and steady clinical updates for ARCT-154 and ARCT-032. Earnings calls, SEC filings, conference posts, and publications kept the pipeline visible and helped investors judge trial risk and cash use. That fits a biotech still driven by milestones.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eFY2025 role\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartners\u003c\/td\u003e\n\u003ctd\u003e7 named alliances\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePipeline\u003c\/td\u003e\n\u003ctd\u003e4 key programs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDisclosures\u003c\/td\u003e\n\u003ctd\u003eClinical proof points\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePrice\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNo public product price\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eArcturus Therapeutics Holdings Inc. has no public consumer price because it is a development-stage biotechnology Company, not a retail seller. Its value is priced through licensing, collaboration, and regulated drug commercialization, not shelf labels. So pricing is not disclosed like a standard consumer product.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePartnership-funded economics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eArcturus Therapeutics Holdings Inc. relies on partner-funded R\u0026amp;D, with collaboration and grant revenue helping finance pre-launch work and reduce dependence on upfront customer sales. In 2024, the company reported $84.5 million of revenue, and much of that came from partnerships tied to its RNA medicine pipeline. That funding model lowers launch risk and smooths cash use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMilestone-based value\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eArcturus Therapeutics Holdings Inc. prices value less like a shelf product and more like a biotech option: payments rise as milestones are hit. In FY2024, R\u0026amp;D expense was $135.2 million, showing how pipeline progress drives economics. That makes pricing strategic, since each clinical win can trigger future cash and better deal terms.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eFuture specialty-market pricing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIf approved, Arcturus Therapeutics Holdings Inc. rare-disease and vaccine assets would likely be priced as specialty drugs, where annual launch prices often sit in the low six figures and can top $500,000 for ultra-rare therapies. The final price will hinge on development cost, clinical benefit, and payer talks, so it could move materially from list price to net price. Arcturus Therapeutics Holdings Inc. has not publicly set a market price in the profile provided.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSpecialty pricing fits rare disease assets.\u003c\/li\u003e\n\u003cli\u003ePayer rebates can cut net price.\u003c\/li\u003e\n\u003cli\u003eNo public price set yet.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAccess and reimbursement driven\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAccess for Arcturus Therapeutics Holdings Inc. depends on payer acceptance, so pricing must match clear clinical value. LUNAR-OTC targets ornithine transcarbamylase deficiency, a rare disorder affecting about 1 in 40,000 births, and LUNAR-CF targets cystic fibrosis, a U.S. market of about 40,000 people. In rare disease, even small label and reimbursement wins can shape launch price and uptake.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReimbursement drives patient access\u003c\/li\u003e\n\u003cli\u003ePrice must reflect proven value\u003c\/li\u003e\n\u003cli\u003eRare disease markets need payer buy-in\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eArcturus Has No Shelf Price—Value Hinges on Pipeline Progress\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eArcturus Therapeutics Holdings Inc. has no public consumer price; its pricing is deal-based, tied to licensing, milestones, and reimbursement. FY2024 revenue was $84.5 million, while R\u0026amp;D expense was $135.2 million, so value is set by pipeline progress, not shelf price. Rare-disease launches would likely use specialty pricing, but net price depends on payer talks.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003ePrice signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2024 revenue\u003c\/td\u003e\n\u003ctd\u003e$84.5 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2024 R\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e$135.2 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCurrent price model\u003c\/td\u003e\n\u003ctd\u003ePartner and milestone based\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLaunch pricing\u003c\/td\u003e\n\u003ctd\u003eSpecialty drug, payer driven\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234039046409,"sku":"arct-marketing-mix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/arct-marketing-mix.webp?v=1785711307","url":"https:\/\/dcfanalyst.com\/products\/arct-marketing-mix","provider":"DCF Analyst","version":"1.0","type":"link"}